Market Overview

Endologix Appoints Jeffrey S. Brown as Chief Operations Officer

Share:

Endologix, Inc. (NASDAQ:ELGX) ("Endologix" or the "Company"), a
developer and marketer of innovative treatments for aortic disorders,
today announced that it has appointed Jeffrey S. Brown as the Company's
Chief Operations Officer, effective as of August 13, 2018.

John Onopchenko, Chief Executive Officer of Endologix, Inc., said, "I am
very excited to have someone with Jeff's credentials and industry
knowledge joining our executive team. His proven track record of
transformational leadership, operational excellence, and delivering
results will be invaluable to Endologix. We remain focused on building a
cohesive team and a strong culture of accountability, while continuing
to innovate and position the Company for further operational
improvements."

Mr. Brown brings to Endologix twenty four years of experience as a
General Manager, Chief Operating Officer, Supply Chain Executive, Sales
Leader, Consultant and Lecturer. Most recently, he was General Manager
of a multi-site joint venture between Johnson & Johnson and Steris
Corporation, where he led significant improvements across operations,
quality, engineering, and supply chain. Prior to that, he was Chief
Operating Officer for Chatham Industries, where he helped successfully
orchestrate a leveraged buyout and turnaround of the firm. Prior to
that, Mr. Brown worked for five years as General Manager at Boston
Scientific Corporation, where he led a critical site transformation and
sat on the global supply chain management board. Mr. Brown also worked
for seven years as Worldwide Operations Manager at Johnson & Johnson and
for five years leading sterilization operations across the U.S., EU, and
Far East for Haemonetics Corporation.

Mr. Brown commented, "I am thrilled to be taking on this critical
leadership role at Endologix, particularly during this transformational
time. I look forward to working with the team to improve operations and
to leverage our talent and innovative technology, with the ultimate goal
of delivering superior products and services to our patients."

Mr. Brown earned his MBA from Babson College, Wellesley, MA and his
Bachelor of Science in Microbiology from University of New Hampshire,
Durham, NH.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments
for aortic disorders. The Company's focus is endovascular stent grafts
for the treatment of abdominal aortic aneurysms (AAA). AAA is a
weakening of the wall of the aorta, the largest artery in the body,
resulting in a balloon-like enlargement. Once AAA develops, it continues
to enlarge and, if left untreated, becomes increasingly susceptible to
rupture. The overall patient mortality rate for ruptured AAA is
approximately 80%, making it a leading cause of death in the United
States. For more information, visit www.endologix.com.

View Comments and Join the Discussion!